THE STATUS OF TREATMENT OF SCHIZOAFFECTIVE DISORDER WITH DEPRESSIVE TYPE

Dương Minh Tâm1,2, Trần Nguyễn Ngọc1,2,
1 Hanoi Medical University
2 National Mental Health Institute, Bach Mai Hospital

Main Article Content

Abstract

We carried out a study with the aim of finding out the status of treatment for schizoaffective disorder with depressive type in inpatients at the Institute of Mental Health - Bach Mai hospital. This is a cross-sectional descriptive study with 40 patients diagnosed with schizoaffective disorder according to ICD-10 diagnostic criteria (F25.1). The results showed that the average age of patients with schizoaffective disorder was 30.3±8.2 years, more common in women than in men, and the female/male ratio ≈ 1.4/1. Among the neuroleptics, risperidone was the most used (60.0%). Among antidepressants, sertraline was used the most (90.0%) with the highest mean dose 125 ± 52.8 mg/day. There were 5 patients treated with valproate (12.5%), the average highest dose was about 1100 ± 223.6 mg/day. Diazepam (a sedative) is also frequently used (87.5%). 100% of patients were treated with neuroleptics in combination with one or more other drugs. The majority of patients received inpatient treatment for 2-4 weeks (60.0%). The average number of treatment days was 20.6 ± 9.3 days, the shortest was 6 days and the longest was 46 days.

Article Details

References

1. Organization WH. The ICD-10 Classification of Mental and Behavioural Disorders: Clinical Descriptions and Diagnostic Guidelines. 1st edition. World Health Organization; 1992.
2. Azorin JM, Kaladjian A, Fakra E. [Current issues on schizoaffective disorder]. L’Encephale. 2005; 31(3):359-365. doi:10.1016/s0013-7006(05)82401-7
3. Association AP. Diagnostic and Statistical Manual of Mental Disorders, 5th Edition: DSM-5. 5th edition. American Psychiatric Publishing; 2013.
4. Levinson DF, Umapathy C, Musthaq M. Treatment of schizoaffective disorder and schizophrenia with mood symptoms. Am J Psychiatry. 1999;156(8):1138-1148. doi:10.1176/ ajp.156.8.1138
5. Levinson DF, Umapathy C, Musthaq M. Treatment of schizoaffective disorder and schizophrenia with mood symptoms. Am J Psychiatry. 1999;156(8):1138-1148. doi:10.1176/ ajp.156.8.1138
6. Benabarre A, Vieta E, Colom F, Martínez-Arán A, Reinares M, Gastó C. Bipolar disorder, schizoaffective disorder and schizophrenia: epidemiologic, clinical and prognostic differences. Eur Psychiatry J Assoc Eur Psychiatr. 2001; 16(3): 167-172. doi:10.1016/s0924-9338(01)00559-4
7. Ndetei DM, Khasakhala L, Meneghini L, Aillon JL. The relationship between schizoaffective, schizophrenic and mood disorders in patients admitted at Mathari Psychiatric Hospital, Nairobi, Kenya. Afr J Psychiatry. 2013;16(2):110-117. doi:10.4314/ajpsy.v16i2.14
8. Di Fiorino M, Montagnani G, Trespi G, Kasper S. Extended-release quetiapine fumarate (quetiapine XR) versus risperidone in the treatment of depressive symptoms in patients with schizoaffective disorder or schizophrenia: a randomized, open-label, parallel-group, flexible-dose study. Int Clin Psychopharmacol. 2014; 29 (3):166-176. doi:10.1097/YIC.0000000000000017